Two weeks ago CytoDyn Inc (OTCMKTS:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human HIV infection, announced that its application for Orphan Drug Designation was not granted by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) because PRO 140 appears to have the potential to treat more than just the subset of multi-drug resistant HIV patients for which the designation was requested.
This was a dynamic designation for CytoDyn which is currently conducting a pivotal Phase 2b/3 trial with PRO 140 in combination with other antiretroviral agents in the patient population submitted to the FDA in the ODD application. However, CytoDyn is also conducting a 300-patient Phase 2b/3 trial with PRO 140 as a single-agent maintenance therapy for HIV-infected patients with a U.S. patient population that far exceeds the 200,000-patient threshold for ODD.
A look at the CytoDyn Inc (OTCMKTS:CYDY) chart below shows trading in CytoDyn shares has not been the same as the rest of the sector, but in reality it is a drug discovery bio-pharma who’s performance will be tied to potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection.
Find out when $CYDY stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
$CYDY 10-Day Chart Below:
The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV indications where CCR5 and its ligand CCL5 may be involved.
PRO 140 belongs to a new class of HIV/AIDS therapeutics – viral-entry inhibitors – that are intended to protect healthy cells from viral infection. PRO 140 is a humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 blocks the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5. Importantly, PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 does not have agonist activity toward CCR5 but does have antagonist activity to CCL5, which is a central mediator in inflammatory diseases. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a “fast track” product candidate by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use.
Many stocks will be affected, as cannabis stocks like CytoDyn Inc (OTCMKTS:CYDY), replace long standing bio- pharma solutions in a natural versus synthetic treatments. This will shift the valuations away from these pharma and bio-pharma names. This shift is already happening which is the catalyst for the increased valuation in the cannabis sector across the board.
The current administration and specifically Jeff Sessions solely has shifted focus for investors into the medical sector versus the touch the plant stocks who are more retail focused. We will be writing about and covering this clear division in the sub sectors of cannabis – so stay tuned – as this new green wave sweeps over investors world wide. For more news on CYDY and other fast-moving penny stocks, please subscribe to OracleDispatch.com below.